[go: up one dir, main page]

MA39957A - Vaccin néonatal - Google Patents

Vaccin néonatal

Info

Publication number
MA39957A
MA39957A MA039957A MA39957A MA39957A MA 39957 A MA39957 A MA 39957A MA 039957 A MA039957 A MA 039957A MA 39957 A MA39957 A MA 39957A MA 39957 A MA39957 A MA 39957A
Authority
MA
Morocco
Prior art keywords
peptides
nucleic acids
relates
women
neonatal vaccine
Prior art date
Application number
MA039957A
Other languages
English (en)
Other versions
MA39957B1 (fr
Inventor
Neves Ferreira Da Silva Paula Maria Das
Pedro Jorge Fonseca Madureira
Original Assignee
Univ Do Porto Reitoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14398006.8A external-priority patent/EP2955194A1/fr
Application filed by Univ Do Porto Reitoria filed Critical Univ Do Porto Reitoria
Publication of MA39957A publication Critical patent/MA39957A/fr
Publication of MA39957B1 publication Critical patent/MA39957B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01022—Lactaldehyde dehydrogenase (1.2.1.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)

Abstract

Cette invention concerne des peptides dérivés d'une protéine ubiquitaire, et des acides nucléiques codant pour ces peptides. L'invention concerne également diverses utilisations de ces peptides et acides nucléiques, par exemple, à titre d'antigènes se prêtant à une utilisation dans des vaccins per se et dans la génération d'anticorps utilisables dans des médicaments thérapeutiques destinés à prévenir, améliorer ou traiter les infections provoquées par des bactéries induisant une septicémie. L'invention profite plus particulièrement aux hôtes immunodéprimés, tels que les nouveau-nés, les bébés, les enfants, les femmes d'âge fertile, les femmes enceintes, les fœtus, les personnes âgées et les diabétiques.
MA39957A 2014-06-12 2015-06-12 Vaccin néonatal MA39957B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14398006.8A EP2955194A1 (fr) 2014-06-12 2014-06-12 Vaccin néonatal
EP15398003 2015-03-30
PCT/EP2015/063243 WO2015189422A1 (fr) 2014-06-12 2015-06-12 Vaccin pour hôtes immunodéprimés

Publications (2)

Publication Number Publication Date
MA39957A true MA39957A (fr) 2017-04-19
MA39957B1 MA39957B1 (fr) 2021-04-30

Family

ID=53385660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39957A MA39957B1 (fr) 2014-06-12 2015-06-12 Vaccin néonatal

Country Status (18)

Country Link
US (3) US11066652B2 (fr)
EP (1) EP3155004B1 (fr)
JP (2) JP6813480B2 (fr)
KR (2) KR20200013809A (fr)
CN (1) CN106795502B (fr)
CA (1) CA2969878C (fr)
CY (1) CY1124388T1 (fr)
DK (1) DK3155004T3 (fr)
ES (1) ES2862534T3 (fr)
HR (1) HRP20210458T1 (fr)
HU (1) HUE053668T2 (fr)
LT (1) LT3155004T (fr)
MA (1) MA39957B1 (fr)
PL (1) PL3155004T3 (fr)
RS (1) RS61549B1 (fr)
SI (1) SI3155004T1 (fr)
SM (1) SMT202100162T1 (fr)
WO (1) WO2015189422A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200013809A (ko) 2014-06-12 2020-02-07 우니베르시다데 도 포르토 면역약화된 숙주용 백신
WO2018127545A1 (fr) * 2017-01-05 2018-07-12 Evaxion Biotech Aps Vaccins ciblant pseudomonas aeruginosa
WO2024229085A2 (fr) * 2023-05-01 2024-11-07 Washington State University Modèle de souris avec télomère humanisé
WO2025051845A1 (fr) 2023-09-06 2025-03-13 Immunethep, Sa Produits et méthodes permettant d'induire des réponses immunitaires à des bactéries

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326407C (fr) * 1998-04-29 2012-09-11 University Of Southern California Vecteurs retroviraux incluant des proteines d'escorte a enveloppe modifiee
MX2007009512A (es) 2005-02-08 2008-02-21 New York Blood Ct Inc Neutralizacion de anticuerpos monoclonales contra coronavirus asociado con sindrome respiratorio agudo severo.
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
ES2298055A1 (es) 2006-08-09 2008-05-01 Fundacion Marques De Valdecilla Peptidos inmunogenicos frente a los generos listeria y mycobacterium, anticuerpos y usos de los mismos.
WO2010150242A2 (fr) * 2009-06-25 2010-12-29 Protea Vaccine Technologies Ltd. Peptides de streptococcus pneumoniae immunogènes et multimères peptidiques
US8715658B2 (en) 2009-08-26 2014-05-06 The Feinstein Institute For Medical Research Methods for treating conditions mediated by the inflammatory cytokine cascade using GAPDH inhibitors
WO2011067758A2 (fr) * 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
US10706955B2 (en) * 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CA3139031A1 (fr) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
KR20200013809A (ko) 2014-06-12 2020-02-07 우니베르시다데 도 포르토 면역약화된 숙주용 백신

Also Published As

Publication number Publication date
US20240191209A1 (en) 2024-06-13
JP2017518769A (ja) 2017-07-13
JP2021000134A (ja) 2021-01-07
RS61549B1 (sr) 2021-04-29
PL3155004T3 (pl) 2021-10-25
HUE053668T2 (hu) 2021-07-28
SI3155004T1 (sl) 2021-08-31
CA2969878C (fr) 2021-05-04
EP3155004A1 (fr) 2017-04-19
KR20200013809A (ko) 2020-02-07
US20220049229A1 (en) 2022-02-17
SMT202100162T1 (it) 2021-05-07
DK3155004T3 (da) 2021-04-06
MA39957B1 (fr) 2021-04-30
CN106795502A (zh) 2017-05-31
US11834684B2 (en) 2023-12-05
US20170191040A1 (en) 2017-07-06
CY1124388T1 (el) 2022-07-22
WO2015189422A1 (fr) 2015-12-17
CN106795502B (zh) 2021-12-14
JP6813480B2 (ja) 2021-01-13
CA2969878A1 (fr) 2015-12-17
KR20170018920A (ko) 2017-02-20
ES2862534T3 (es) 2021-10-07
US11066652B2 (en) 2021-07-20
LT3155004T (lt) 2021-03-25
EP3155004B1 (fr) 2021-01-13
HRP20210458T1 (hr) 2021-05-14

Similar Documents

Publication Publication Date Title
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
BR112015023105A2 (pt) construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a?
BR112018073843A2 (pt) anticorpos de peptídeo beta amiloide anti-n3pglu e usos dos mesmos
MA44059B1 (fr) Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
BR112018067792A2 (pt) preparação contendo o anticorpo
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
EA201071365A1 (ru) Моноклональные антитела, имеющие гомоподтип кросс-нейтрализующих свойств против вируса гриппа а подтипа н1
MA39957A (fr) Vaccin néonatal
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
EA201591579A1 (ru) Способы лечения болезни крона при помощи анти-il-23 антитела
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
TR201911232T4 (tr) Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler.
BR112014032682A2 (pt) anticorpo monoclonal humano contra a proteína vp1 do vírus jc
EP4512477A3 (fr) Constructions de lampe améliorées
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
MX2021010021A (es) Proteínas sintéticas autoensamblables.
BR112021026364A2 (pt) Antígenos de câncer e métodos
EA201401352A1 (ru) Вакцина против вируса шмалленберга (sbv), способы ее получения и применения
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
MX376293B (es) Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.